In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target ...

Globus Medical GMED has entered into a definitive agreement to acquire Nevro Corp. NVRO in an all-cash transaction valued at approximately $250 million. Under the terms of the agreement, unanimously ...

周一，Jefferies分析师Matthew Taylor调整了Nevro Corp (NYSE: NVRO )的股票评级，从"减持"上调至"持有"。同时，目标价也从此前的$4.50上调至$5.85。这一调整是在Nevro最近宣布被GMED收购后做出的，Taylor对GMED持积极态度。目前，Nevro股价报$5.72，过去一周强劲上涨14.86%。根据 InvestingPro ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Globus Medical (GMED – Research Report) and ...

周四，Canaccord Genuity维持Globus Medical (NYSE: GMED )的买入评级，目标价为101.00美元。该公司目前股价为88.54美元。该机构的分析支持公司当前战略，特别是在收购Nevro Corp之后。Canaccord Genuity对Globus ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

The company currently has its sales operations distributed across 51 counties worldwide. GMED is a #3 (Hold) on the Zacks Rank, with a VGM Score of A. Momentum investors should take note of this ...

Stock analysts at Roth Capital dropped their FY2024 earnings per share (EPS) estimates for shares of Globus Medical in a ...

Globus Medical (GMED) has agreed to buy Nevro (NVRO) through an all-cash deal valued at around $250M. Read more here.

Jefferies analyst Matthew Taylor revised the stock rating for Nevro Corp (NYSE:NVRO), elevating it from Underperform to Hold. Accompanying this upgrade, the price target also saw an increase to $5.85, ...

The company currently has its sales operations distributed across 51 counties worldwide. GMED is a Zacks Rank #3 (Hold) stock, with a Growth Style Score of A and VGM Score of A. Earnings are expected ...